Omnicell shares surged 14.5% following first-quarter results that landed at or above the high end of prior guidance across all key metrics. The market reacted positively to accelerating momentum in core businesses, execution on reoccurring revenue growth, and notable wins with enterprise healthcare systems.

• Q1 revenue reached $310 million, with non-GAAP EBITDA of $45 million and non-GAAP EPS of $0.55, all at or above prior guidance ranges.
• Management highlighted expanding recurring revenue and successful deployment of OmniSphere, its cloud-native medication management platform, as strategic growth drivers.
• The quarter featured competitive wins, including expanded adoption by the U.S. Department of Veterans Affairs and a major New York academic medical center, signaling continued customer traction.
• The newly introduced Titan XT automated dispensing system, built on the OmniSphere platform, targets enterprise-level customers seeking improved workflows and system-wide visibility.
• Management cited disciplined cost controls and progress toward larger strategic goals, while emphasizing Omnicell’s increasing role as a technology and service partner to large healthcare organizations.